Actithera, a radiopharmaceutical startup with bases in Oslo and Cambridge, has raised nearly $76 million in Series A funding to develop experimental cancer drugs targeting fibroblast activation protein (FAP). These drugs aim to remain localized within tumors longer by targeting proteins involved in tumor growth, potentially overcoming barriers to immune and therapeutic access. Radiopharmaceuticals deliver tumor-killing radiation precisely, gaining momentum after recent commercial successes. Although manufacturing complexities and isotope logistics remain challenges, Actithera's funding will support progression toward clinical trials and expansion of their drug pipeline.